New GLP1 pill helps patients lose up to 8% of body weight, trial shows

Daily orforglipron tablets led to greater weight loss than semaglutide tablets, offering potential oral alternative to Wegovy and Mounjaro A new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for a non-injection alternative to Wegovy and Mounjaro. The drug, called orforglipron and manufactured by Eli Lilly, is prescribed for type 2 diabetes and targets the same GLP-1 receptors as oral semaglutide. Like semaglutide, it low...

By Anna Bawden Health and social affairs correspondent

Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch.

People with diabetes lost an average of nearly 20 pounds of body weight during a clinical trial of orforglipron, which is a new small molecule GLP-1 drug. colnihko/Getty Images Eli Lilly's new GLP-1 pill surged ahead of competitor Novo Nordisk's in a head-to-head trial. Patients on Lilly's pill had better blood sugar levels, lost more weight, and improved heart health. The pill, which analysts say might cost $300 a month, could be available as soon as mid-2026. Better injections and better ...